期刊文献+

沙利度胺对小鼠恶性黑色素瘤生长及血管生成模式的影响 被引量:1

Influence of Thalidomide on Tumor Growth and Angiogenesis Patterns of Melanoma
在线阅读 下载PDF
导出
摘要 目的:观察沙利度胺对恶性黑色素瘤(恶黑)生长及血管生成模式的影响,为对其治疗提供实验依据。方法:B16黑色素瘤移植瘤模型C57小鼠35只,随机分为实验组20只,对照组15只,分别给予沙利度胺及0.5%羧甲基纤维素钠溶液灌胃。计数肿瘤组织中内皮依赖性血管、马赛克血管和血管生成拟态数目及肿瘤细胞坏死情况,并进行血管内皮细胞生长因子(VEGF)、核因子(NF)-κB、基质金属蛋白酶(MMP)-2、MMP-9和增殖细胞核抗原(PCNA)的免疫组化染色。结果:给药9d后,实验组小鼠的肿瘤体积明显小于对照组(P<0.05)。实验组内皮依赖性血管、马赛克血管和血管生成拟态数量显著低于对照组(P<0.05),且实验组VEGF、NF-κB、PCNA、MMP-2及MMP-9的表达也明显低于对照组(P<0.05)。实验组肿瘤组织中坏死细胞数明显高于对照组(P<0.05)。结论:沙利度胺可以抑制恶黑血管生成,促进肿瘤细胞的坏死,抑制肿瘤的生长。 Objective:To investigate the influence of thalidomide on the tumor growth and angiogenesis of melanoma,and provide experimental evidence for clinical treatment of melanoma.Methods:Thirty-five C57 mice of the melanoma transplanted model were lavaged by thalidomide and 0.5% carboxymethyl cellulose(CMC).The vasculogenic mimicry,mosaic vessel,endothelial dependent vessel and necrosis ratio of tumor were measured by HE staining.The expression levels of matrix metalloproteinases(MMP)-2,MMP-9,vascular endothelial growth factor(VEGF),nuclear factor(NF)-κB and proliferating cell nuclear antigen(PCNA) were examined by immunohistochemistry.Results:The tumor volume was significantly decreased in experiment group 9 days after treatment compared with that of control group(P 0.05).The count values of vasculogenic mimicry,mosaic vessel and endothelial dependent vessel were significantly decreased in experiment group compared with those of control group(P 0.05).The necrosis ratio of tumor was increased in experiment group compared with that of control group(P 0.05).The expression levels of MMP-2,MMP-9,VEGF,NF-κB and PCNA of tumor tissues were significantly decreased in experiment group compared with those of control group(P 0.05).Conclusion:Thalidomide could inhibit angiogenesis,promote tumor cell necrosis and inhibit tumor growth in melanoma.
出处 《天津医药》 CAS 北大核心 2010年第12期1083-1086,共4页 Tianjin Medical Journal
关键词 沙利度胺 黑色素瘤 实验性 新生血管化 病理性 内皮 血管 NF-ΚB 疾病模型 动物 小鼠 近交C57BL thalidomide melanoma experimental neovascularization pathologic endothelium vascular NF-kappa B disease models animal mice inbred C57BL
  • 相关文献

参考文献3

二级参考文献32

  • 1Santos-Mendoza T, Favila-Castillo L, Oltra A, Tamariz J,Labarrios F, Estrada-Parra S, Estrada-Garcia L. Thalidomide and its metabolites have no effect on human lymphocyte proliferation. Int Arch Allergy Immunol 1996; 111:13-17.
  • 2BeIo AV, Ferreira MA, Bosco AA, Machado RD, Andrade SP.Differential effects of thalidomide on angiogenesis and tumor growth in mice. Inflammation 2001; 25:91-96.
  • 3Stephens TD, Bunde CJ, Fillmore BJ. Mechanism of action in thalidomide teratogenesis. Biochem Pharmacol 2000; 59:1489-1499.
  • 4Yamaguchi R, Yano H, Nakashima Y, Ogasawara S, Higaki K,Akiba J, Hicklin DJ, Kojiro M. Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues. Oncol Rev 2000: 7: 725-729.
  • 5Shimamura T, Saito S, Morita K, Kitamura T, Morimoto M,Kiba T, Numata K, Tanaka K, Sekihara H. Detection of vascular endothelial growth factor and its receptor expression in human hepatocellular carcinoma biopsy specimens. J Gastroenterol Hepatol 2000; 15:640-646.
  • 6Poon RT, Ng IO, Lau C, Yu WC, Fan ST, Wong J. Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am 1 Sure 2001: 182: 298-304.
  • 7uMeierhofer C, Dunzendorfer S, Wiedermann CJ. Theoretical basis for the activty of thalidomide. BioDrugs 2001; 15:681-703.
  • 8PoweII EE, Edw~ards-Smith CJ, Hay JL, Clouston AD,Crawford DH, Shorthouse C, Purdie DM, Jonsson JR. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000; 31:828-833.
  • 9Raufman JP, Lamps LW. Thalidomide-induced normalization of serum ALT levels in a patient with hepatitis C. Am J Gastroenterol 2001; 96:3209-3211.
  • 10Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992; 3:65-71.

共引文献74

同被引文献25

  • 1李瑞.药理学[M].北京:人民卫生出版社,2007:300-304.
  • 2Yu J, Liu F, Sun Z, et al. The enhancement of radiosensitivity in human esophageal carcinoma cells by thalidomide and its potential mechanism[J]. Cancer Biother&Radiopharm aceuticals,2011,26(2) : 219 - 227.
  • 3Burris HA, Jones SF, Shipley D, et al. Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer[J]. Cancer Invest,2010,28 (4): 408 -412.
  • 4Kraemer A, Hauser S, Kim Y, et al. Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide[J]. Ger Med Sci, 2009,7: Doc04.
  • 5Meng LJ, Wang J, Fan WF, et al. Evaluation of oral chemotherapy with capecitabine and cyclophosphamide plus thalidomide and prednisone in prostate cancer patients[J]. J Cancer Res Clin Oncol, 2012, 138(2): 333 -339.
  • 6Gilbert MR,Gonzalez J,Hunter K,et al. A phase I factorial design study of dose- dense temozolomide alone and in combination with thalido- mide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma[J]. Neuro Oncol, 2010, 12 (11): 1 167 - 1 172.
  • 7Kim CY, Kim SK, Phi J, et al. A prospective study of temozolomide plus thalidomide during and after radiation therapy for pediatric diffuse pontine gliomas: preliminary results of the Korean Society for Pediatric Neuro - Oncology study [ J ]. J Neurooncol, 2010,100(2): 193 - 198.
  • 8Lutzky J, Weber R, Nunez Y, et al. A phase 1 study of granulocyte macrophage colony - stimulating factor(sargramostim)and escalating dos- es of thalidomide in patients with high- risk malignant melanoma[ J]. J Immunother, 2009,32( 1 ) : 79 - 85.
  • 9Ruan J, Martin P, Coleman M, et al. Durable Responses with the Metro- nomic Regimen RT- PEPC in Elderly Patients with Recurrent Mantle Cell Lymphoma [ J]. Cancer, 2010,116 ( 11 ) : 2 655 - 2 664.
  • 10Cheson BD, Homing S J, Coiffier B, et al. Report of an international work- shop to standardize response criteria for non - Hodgkin's lymphomas[J]. Journal of Clinical Oncolov, 1999,17 (4) : 1 244 - 1 253.

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部